Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 October 2020 | Story Leonie Bolleurs | Photo Supplied
Vicky Simpson believes our current reality is temporary and that we are more than capable to adjust, regardless of our understanding of what ‘normal’ is.

Vicky Simpson is Development Officer in the Office for Institutional Advancement at the university, where one of her main focus areas is to secure funding for UFS projects and raising funds for student bursaries and the No Student Hungry Programme. 

Simpson, an energetic and proactive person who has a passion for interventions that are humanitarian in nature, says she considers herself lucky to be able to align that which she is passionate about with her career, where she can promote the greater good and create opportunities for others.

“I love working with people and I draw energy from interpersonal interactions. I am an extrovert.”

But the strict lockdown regulations implemented by government in March due to the COVID-19 pandemic, which limited personal interaction – dampened Simpson’s enthusiasm for life.

“The side effect was constant snacking – given that the fridge was next to my temporary office. My energy took a dip and I gained weight.”

Keeping positive

“My partner being a frontline medical worker added additional challenges, given that we had to implement strict routines to keep COVID-19 out of our home. We were both rather drained and had to find ways to keep each other positive.”

Practical as she is, Simpson determined that she craved interaction and fresh air.

“I decided to do video calls with friends and family. This made up for the lack of social contact.”

For fresh air, Simpson started a light exercise routine once South Africans were allowed to go for walks, and gradually increased it. “Exercise and healthy nutritional choices lifted my mood. Basically, I used my time wisely and decided to change my routine for the better,” Simpson adds.

She says the key is to set small goals and to take things slowly. “One small victory at a time.” 

Healthy choices

The pandemic challenged Simpson to embrace a more active lifestyle. “The situation forced me to do introspection, self-care, and nurturing,” she says.

Her advice to others is to make the tough choices. “It is easy to get caught up in a routine where you can’t find the time to go for a walk. Evaluate your routine. Start slowly. And do not forget to drink lots of water, take your vitamins, and eat healthier,” she adds.

Simpson explains that she started off by walking only 30 minutes every second day. But once the serotonin bug bit her, she was hooked. Now she goes for a 5 km run at least once a week. “I simply want to feel healthier again,” she says.

She believes our current reality is temporary and she is looking forward to life after lockdown. 

And what is she looking forward to most? Seeing other people smile. “Yes, I randomly smile at strangers. They always smile back. There is not enough love in this world and small things go a long way,” she says.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept